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SREBP-2/PNPLA8 axis improves 
non-alcoholic fatty liver disease 
through activation of autophagy
Kwang-Youn Kim1, Hyun-Jun Jang1, Yong Ryul Yang1, Kwang-Il Park2, JeongKon Seo3,  
Il-Woo Shin4, Tae-Il Jeon5, Soon-cheol Ahn6, Pann-Ghill Suh1, Timothy F. Osborne7 &  
Young-Kyo Seo1
Dysregulated autophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), 
however the mechanisms connecting them remain poorly understand. Here, we show that co-
administration of lovastatin and ezetimibe (L/E) significantly reverses hepatic triglyceride accumulation 
concomitant with an increase in SREBP-2 driven autophagy in mice fed a high-fat diet (HFD). We 
further show that the statin mediated increase in SREBP-2 directly activates expression of patatin-
like phospholipase domain-containing enzyme 8 (PNPLA8) gene, and PNPLA8 associates with 
autophagosomes and is associated with a decrease in cellular triglyceride. Moreover, we show that 
over-expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in 
hepatocytes of HFD-fed mice. Live-cell imaging analyses also reveal that PNPLA8 dynamically interacts 
with LC3 and we suggest that the SREBP-2/PNPLA8 axis represents a novel regulatory mechanism for 
lipid homeostasis. These data provide a possible mechanism for the reported beneficial effects of statins 
for decreasing hepatic triglyceride levels in NAFLD patients.
Obesity is becoming an increasingly important clinical and public health challenge worldwide1–3. Metabolic stud-
ies have suggested that obesity is associated with a high risk of development of life-threatening diseases such 
as type 2 diabetes, hypertension, coronary artery disease, and heart failure. There is also a strong relationship 
between lipid metabolism and many physiologic and pathophysiologic processes4. The mammalian liver accu-
mulates excess lipids as a consequence of common metabolic imbalances that occur with obesity, type 2 diabetes 
and direct lipid disorders. This is often referred to as non-alcoholic fatty liver disease (NAFLD) and cellular lipid 
overload can be detrimental to normal cell function in a variety of different tissues, as described by the “lipotox-
icity hypothesis”5. Despite general agreement that aberrant regulation of cellular lipid contributes to diverse dis-
eases the underlying molecular mechanisms are multifaceted and remain somewhat controversial6,7. Excess lipid 
accumulation results from improper cellular lipid handling export, from altered synthesis, storage or oxidation 
in response to cellular regulatory cues. A part of the cellular adaptive response includes regulation of key lipid 
synthetic genes by the sterol regulatory element binding proteins (SREBPs)8,9.
SREBPs comprise a three-member transcription factor family that play key roles in lipid homeostasis8,9. 
SREBPs are basic helix–loop–helix leucine zipper transcription factors10,11, and mammals express three major iso-
forms that are encoded by two genes. The Srebf-1 gene produces two overlapping mRNAs that differ only in their 
5′ -terminal exons. The resulting proteins SREBP-1a and SREBP-1c are identical, except for unique amino-termini 
of their transcriptional activation domains. In addition, a separate Srebf-2 gene encodes a single SREBP-2 protein. 
In a previous paper, we described a genome-wide binding/ChIP-Seq analysis of SREBP-2 in mouse liver chroma-
tin that revealed SREBP-2 occupied the promoters of several autophagy-related genes12,13. We also showed that in 
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cholesterol-depleted cells, SREBP-2 knockdown reduced autophagosome formation and lipid droplet association 
with the autophagosome protein LC3. This is consistent with a more general role for SREBP-2 in autophagy to 
regulate lipid mobilization. However, how SREBP-2 might connect lipid breakdown with autophagy remained 
unclear.
Recent studies have shown that patatin-like phospholipase domain-containing enzyme 5 (PNPLA5) plays 
important roles in both TAG metabolism and LD homeostasis14,15. PNPLAs contain a conserved serine lipase 
motif (Gly-x-Ser-x-Gly) and exhibit acyl-hydrolase activity16–18. Nine PNPLA family members (PNPLA1–9) have 
been identified in various tissues in humans and they play important roles in various cellular processes. PNPLA3 
is associated with NAFLD in humans, possesses both acyl hydrolase and synthesis activity in partially purified 
form, and is regulated in the liver by SREBP-1c during the insulin dependent fasting/feeding cycle19. PNPLA8 
(also known as iPLA2γ ) preferentially acts on arachidonic acid (AA) containing membrane phospholipids (PL) 
to generate free AA along with lysophosphatidic acid (LPA). AA can be converted into biologically active prosta-
glandins20–22 and there is also compelling evidence suggesting that PNPLA8 may also be involved in the regula-
tion of signal transduction, cell growth, gene expression, and innate immune and inflammatory reactions possibly 
through regulation of the PI3K-TORC1 pathway22. Although TORC1 is a major regulator of autophagy initiation 
through phosphorylating ULK1/2, a direct role for PNPLA8 in autophagosome formation has not been reported.
Here, we provide evidence for PNPLA8 as a candidate enzyme that links lipid metabolism and autophagy 
initiation. We show that PNPLA8 is a direct SREBP-2 target gene and that induction of PNPLA8 in the livers of 
mice fed with a chow diet supplemented with lovastatin plus ezetimibe (L/E) or direct introduction of PNPLA8 
into livers of HFD fed mice decreases hepatic lipid accumulation. We further show that PNPLA8 contributes to 
lipid droplet mobilization in mouse primary hepatocytes where it dynamically associates directly with autophago-
somes. The SREBP-mediated induction of PNPLA8 provides a possible mechanistic understanding for the effec-
tiveness of statin therapy in reducing hepatic lipid levels in patients with hypercholesterolemia and NAFLD3,23.
Results
Lovastatin attenuates hepatic lipid accumulation in a high-fat diet mouse model. In a prior 
study, we showed that treating chow fed mice with lovastatin plus ezetimibe (LE) increased expression of auto-
phagy genes through SREBP-212. To determine how this might alter hepatic lipid storage, we examined the effects 
of LE treatment on hepatic lipid accumulation in mice consuming a high- fat diet (HFD). Therefore, mice were 
fed a HFD for 12 weeks and separated into two groups and the HFD was continued except one group was sup-
plemented with an oral gavage of L/E to inhibit cholesterol production in the liver and simultaneously limit 
cholesterol uptake from the diet. The other group was treated with a vehicle as a control. Mice were gavaged every 
third day and sacrificed after a total of 12 days. Gross evaluation showed the pale liver appearance consistent 
with excess hepatic lipid accumulation in the control mice (Fig. 1a). Hematoxylin-eosin (H&E) staining and 
direct measurements of hepatic lipid levels were consistent with reduced lipid overload in the LE treated group 
(Fig. 1b–d). As expected, SREBP-2, but not SREBP-1c, mRNA and nuclear protein levels were increased by the 
LE treatment as well (Fig. 1e). Taken together, these results suggest that SREBP-2 induction is associated with a 
decrease in hepatic lipid in response to the nutrient overload of HFD.
Because our prior study suggested SREBP-2 might increase lipid droplet turnover by activating genes of auto-
phagy and depletion of lipids has been shown to increase autophagy, we proposed that SREBP-2 activation in 
response to LE supplementation might induce autophagy to limit HFD associated liver lipid accumulation.
Statin induces autophagy in primary hepatocytes. To evaluate the effects of statins on autophagy 
and hepatic lipid accumulation, we treated primary hepatocytes from HFD fed mice with increasing concen-
trations of lovastatin and measured autophagy using acridine orange (AO) which turns from green in healthy 
cells to orange as it accumulates in acidic vesicular organelles (AVOs). Figure 2a shows that the percentage of 
AO-positive primary hepatocytes detected via flow cytometry, was increased by lovastatin in a dose-dependent 
fashion. When MPH were treated with the autophagy inhibitor, 3-methyladenine (3-MA), the percentage of sta-
tin induced AO positive cells declined from 25.12% to 14.65% (Fig. 2b). Next, AVO formation was also analyzed 
in cells via confocal microscopy. Vehicle-treated cells exhibited green fluorescence with minimal red fluorescence, 
whereas cells treated with 5 or 10 μ M statin exhibited an increase in red fluorescence consistent with elevated 
AVO formation (Fig. 2c). In addition, the autophagy-specific markers Atg5, Atg7, and LC3B were also increased 
as measured via immunoblotting analysis (Fig. 2d). Taken together, these results suggest that statin treatment of 
mouse hepatocytes increases autophagy. Because LC3 accumulation can also occur when autophagy is blocked, 
we evaluated the effects of PNPLA8 and statins on triglyceride levels in HepG2 cells after treatment with pal-
mitic acid to induce autophagy. We transfected cells with aiRNAs to knockdown PNPLA8 prior to palmitic acid 
treatment. After 24 hr of palmitic acid (400 uM, treatment), HepG2 cells were treated with statins (5 uM) in the 
presence and absence of chloroquine (50 uM) and endogenous triglyceride (TG) levels were measured over the 
time points of 0 to 16 hr. Consistent with lipid turnover through autophagy, chloroquine treatment blocked the 
decrease in TG levels observed similar to what occurred when PNPLA8 was reduced through si-RNA mediated 
knockdown (Supplementary Fig. S1a). We also measured LC3B conversion in this experiment and consistent 
with statin treatment leading to increased autophagic flux, LC3IIB levels were further increased by chloroquine 
(Supplementary Fig. S1b).
SREBP-2 regulates expression of PNPLA8. We previously reported the genome-wide binding patterns 
of SREBP-2 in hepatic chromatin and uncovered a preferred binding motif12,24. To find a SREBP-2-regulated 
gene that might contribute to lipid hydrolysis and be responsible for the decrease in hepatic lipid accumulation 
following LE treatment in HFD mouse liver, we reviewed our previous genome-wide analysis of SREBP-2 locali-
zation and found a highly enriched SREBP-2 binding peak at the Pnpla8 promoter (Fig. 2e). A gene-specific ChIP 
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Figure 1. Lovastatin reverses hepatic lipid accumulation in mice fed with a high-fat diet (HFD). Mice were 
fed a HFD for 12 weeks followed by gavage administration of either vehicle control or a mixture of lovastatin 
and ezetimibe (L/E) three times (days 1, 4, 8) and all mice were sacrificed on day 12. Chow diet mice were used 
as basal controls. The livers from chow, HFD or HFD with L/E treated mice (a) and hematoxylin and eosin 
(H&E)-stained sections of a representative liver from chow, HFD or HFD L/E group (b). Hepatic triglyceride 
(c) and cholesterol levels (d) from the different groups are presented. Striped, open, and filled bars denote chow, 
HFD, and HFD + L/E groups, respectively. (e) SREBP-2 and SREBP-1c mRNA levels were analyzed in mice fed 
with HFD (open bars) or HFD + L/E (filled bars). Immunohistochemical analysis of livers from mice fed with 
HFD or HFD plus L/E using an anti-SREBP-2 antibody was performed as described in materials and methods. 
All data are representative of at least three independent experiments. Student’s t-test was used for the statistical 
analysis. Data are shown as means ± standard deviations. *p < 0.05, **p < 0.01.
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Figure 2. Statin induces autophagy in primary hepatocytes and Pnpla8 is upregulated by SREBP-2. Mouse 
primary hepatocytes (MPH) were prepared from HFD treated mice and dishes were incubated with different 
concentrations of lovastatin for 24 hr and then analyzed. (a) Acidic vacuoles (AVOs) were measured using 
acridine orange (AO) staining. Cells were analyzed by flow cytometry and the percentage of AO positive cells 
was determined. (b) Dishes were treated with vehicle or 1 mM 3-MA for 1 h prior to AO staining and flow 
cytometric evaluation. The red arrow indicates AO staining was reduced from 25.12% to 14.65% by 3-MA. (c) 
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analysis with chromatin from statin treated primary hepatocytes and primers flanking this region confirmed 
SREBP-2 binding to the Pnpla8 gene promoter (Fig. 2f). The binding enrichment was comparable to SREBP-2 
binding at known SREBP-2 regulated the promoters for HMGCR and LDLR (Fig. 2f). To determine whether 
SREBP-2 activates expression of PNPLA8 or any other PNPLA family members, we measured expression of 7 
PNPLA-encoding genes in control and statin treated primary hepatocytes and as shown in Fig. 2g, Pnpla8 and 
Pnpla3 mRNA expression levels were both induced by statin treatment. PNPLA8 protein levels were also increased 
by statin treatment (Fig. 2h). We previously reported that SREBP-1 binds and activates the PNPLA3 promoter, 
however, this is the first demonstration that SREBPs might activate expression of PNPLA8. The sequence com-
parison in Fig. 2e suggests the human PNPLA8 gene might also be SREBP responsive, thus we transfected a FLAG 
epitope-tagged SREBP expression vector into human 293T cells and measured the endogenous levels of PNPLA8 
proteins via Western blot analysis. We found that the accumulation of nuclear FLAG-tagged SREBP-2 was accom-
panied by an increase in both PNPLA8 protein and mRNA levels (Supplementary Fig. S2a,b).
PNPLA8 induction reduces lipid accumulation in hepatocytes from HFD liver. Next, we analyzed 
how activation of endogenous SREBP-2 in primary hepatocytes would influence the endogenous expression of 
PNPLA8, lipid accumulation, and autophagy. Primary hepatocytes from HDF mice were transfected with a con-
trol siRNA or a siRNA targeting PNPLA8 and then cultured in medium without sterols but with lovastatin (5 μ 
M) and endogenous triglyceride levels were followed over the course of 16hr. (Fig. 3a). The statin treatment 
resulted in a transient increase in PNPLA8 protein (Fig. 3b) and this was accompanied by a transient decrease in 
cell TG levels (Fig. 3a). Importantly, the knockdown of PNPLA8 prevented the decrease in TG similar to what we 
observed previously when SREBP-2 was depleted in a similar experiment12. When the effect of statin treatment on 
PNPLA8 expression was monitored using immunofluorescence and cell lipids were analyzed via the fluorescent 
lipophilic dye BODIPY, we observed that an increase in PNPLA8 expression was associated with a reduction in 
bodipy staining lipid droplets (Fig. 3c). Figure 3d confirms that autophagy markers were increased by statin treat-
ment and a knockdown of PNPLA8 blunts the induction (Fig. 3e). An siRNA knockdown of SREBP-2 blunted the 
induction of PNPLA8 by statin treatment and also reduced the number of acridine orange positive cells (Fig. 3f,g). 
This is consistent with SREBP-2 acting upstream of PNPLA8 in the statin dependent induction of autophagy.
PNPLA8 regulates lipid metabolism in vivo. To determine whether altered expression of PNPLA8 mod-
ulates lipid accumulation and autophagy in mouse liver, we injected vectors expressing GFP as a control or a 
PNPLA8 – GFP chimeric protein into mice using in vivo-jetPEI (see Materials and Methods). Briefly, mice were 
fed HFD for twelve weeks and then 100 μ g plasmid DNA/100 μ l was delivered via tail vein injections on days 1, 
4 and 8 and mice were sacrificed on day 12. Hepatocytes were isolated and expression of PNPLA8-GFP in the 
hepatocytes was confirmed by fluorescent microscopy (Supplementary Fig. S3). Histological analysis (H&E stain-
ing) and biochemical measurements were consistent with PNPLA8 expression leading to a decrease in hepatocyte 
TG (Fig. 4a–c).
To visualize the intracellular distribution of lipid droplets more directly, confocal live cell imaging was per-
formed in MPH isolated from control and GFP-PNPLA8 injected HFD fed mice using BODIPY to visualize 
lipid droplets and GFP fluorescence to localize PNPLA8. The BODIPY fluorescence levels were much lower in 
images of PNPLA8-overexpressing hepatocytes than in images of control hepatocytes (Fig. 4d,e) consistent with 
PNPLA8 expression leading to a reduction in intracellular lipid TG levels.
PNPLA8 induces hepatocyte autophagy. To investigate whether over-expression of PNPLA8 directly 
affects autophagy, the formation of LC3 puncta was compared in primary hepatocytes from GFP or PNPLA8-GFP 
expressing livers using confocal imaging for GFP and LC3B. The results in Fig. 5a–c show a 40% increase in LC3B 
puncta in PNPLA8 expressing sample. Next, autophagy was analyzed by accumulation of AVOs by flow cytom-
etry following AO staining (Fig. 5d,e). There was a 30% increase in AO positive cells in the PNPLA8-expressing 
cells (Fig. 5e). Consistent with an increase in autophagy, expression of autophagy markers Beclin-1, Atg5, Atg7, 
and LC3B were all elevated in PNPLA8 expressing hepatocytes as demonstrated via immunoblotting analysis 
(Fig. 5f).
The serine lipase motif of PNPLA8 is required for lipid mobilization but not autophagosome 
association. Pnpla8 contains a conserved serine lipase motif (Gly-x-Ser-x-Gly), which is required 
Dishes were prepared for confocal imaging of AO staining acidic vacuoles (red) and live cells (green).  
(d) Cell extracts were analyzed by immunoblotting to measure the autophagy-related proteins Atg5, Atg7, 
and LC-3B. (e) A genome browser view of SREBP-2 ChIP-Seq read mapping data (Seo et al.12) (11) detected a 
peak around SREBP-2 consensus sequence within the Pnpla8 promoter (chr12:45370150-45370250). (f) Gene-
specific manual ChIP analysis in hepatic chromatin from HFD + L/E-treated group was performed using an 
antibody against SREBP-2 (filled bars) or control IgG (open bars). Gene-specific primers for known SREBP 
binding peaks in the indicated promoter regions were used in the qPCR. Data are shown as means ± standard 
deviations. *p < 0.05. All data are representative of three independent experiments. (g) RNA harvested from 
mouse primary hepatocytes from HFD treated mice cultured for 24hr in the presence of sterols (open bars) or 
the absence of sterols plus 5 uM lovastatin for 24 hr. (filled bars) was subjected to Pnpla gene expression profiling 
via q-PCR. Target gene expression levels were normalized to levels of the housekeeping gene Rplpo using the 
Δ Ct method. (h) MPH from HFD treated mice were cultured for 24 hr with media containing sterols or sterol 
depleted media containing 5 uM lovastatin and PNPLA8 protein were measured.
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for its acyl hydrolase activity18. To explore whether the lipase motif of Pnpla8 was required for lipid drop-
let association and autophagy induction, we deleted the serine lipase motif in an otherwise WT cDNA 
(pCMV-PNPLA8-Δ S493-GFP) (Fig. 6a) and evaluated the effects on AVO formation using AO. Figure 6b–d 
show the lipase motif is required for AVO formation and a reduction in cellular bodipy staining. However, 
interestingly, the deletion of the lipase motif did not impair co-localization with LC3B (Fig. 6e) indicating that 
PNPLA8 can associate with autophagosomes independently of inducing lipid turnover.
To evaluate the PNPLA8-LC3B interaction dynamically in living cells, we performed time-lapse video micros-
copy with cells co-expressing labeled GFP-PNPLA8 (green) and RFP-LC3 (red). Still images captured over time 
Figure 3. PNPLA8 expression correlates with lipid droplet depletion in primary hepatocytes. MPH from 
HFD treated mice were transfected with a control or PNPLA8 siRNA for 24 hr and then cultured with medium 
supplemented with lipid-depleted media and lovastatin (final 5 uM) for the indicated times. (a) Triglyceride levels 
(TG) were measured in total cell lysates and plotted as a relative level of the starting value which was 154 mg/g 
protein. (b) Pnpla8 protein levels were measured as indicated time points. (c) The MPH were cultured with ( + ) 
or without (− ) statin as shown in a and evaluated for the localization of lipid droplets (BODIPY 493/503, red 
and PNPLA8 (green). (d) Whole cell lysates were analyzed for autophagy related-proteins via immunoblotting. 
(e,f) Immunoblots for autophagy-related proteins from primary hepatocytes cultured as above and treated for 
24 hr with si-control or si-PNPLA8. (g) The AO positive cells with (5 uM) or without lovastatin were compared 
to siSREBP2 –treated dish. All data are representative of three independent experiments. Data are shown as 
means ± standard deviations. *p < 0.05.
www.nature.com/scientificreports/
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(Fig. 6f) from the videos available in Supplementary Video S1a and b show that PNPLA8 and LC3 interact tran-
siently in a highly dynamic fashion.
Pnpla8 preferentially releases arachidonic acid and LPA from PL hydrolysis18. These are signaling lipids 
that are known to regulate PI3K signaling. Because PI3K signaling through TORC1 leads to phosphorylation 
and inactivation of the autophagy initiator protein ULK1, we reasoned that PNPLA8 might activate autophagy 
through inhibiting ULK1 phosphorylation downstream of TORC1. Consistent with this model, the phospho-
rylation of AKT, mTOR (Fig. 7a,b) and ULK1 (Fig. 7a,c) in insulin treated cells was significantly reduced by 
co-transfection of wild type PNPLA8 but not the mutant form lacking the lipase motif. This was also confirmed 
by comparing p-ULK1 GFP localization in cells transfected with the GFP tagged WT PNPLA8 versus the lipase 
deficient mutant (Fig. 7d). Taken together, these results suggest PNPLA8 inhibits the activation of mTOR, which 
would lead to reduced phosphorylation of ULK1, and increased autophagy.
Discussion
The connection between lipid depletion and autophagy has been known for a decade and the induction of auto-
phagy directly by statin treatment has also been widely reported23,25,26. However, the underlying molecular mech-
anism is not well understood. In a previous report, we analyzed the binding of SREBP-2 to hepatic chromatin 
prepared from livers of mice fed a chow diet supplemented with lovastatin and ezetimibe (LE)12. Interestingly, 
we demonstrated that SREBP-2 binds to and activates expression of several autophagy genes. Because SREBP-2 
activity is increased upon low sterol levels to stimulate expression of genes required to provide the cell with new 
lipid, we reasoned that SREBP-2 activation of genes that promote lipid droplet mobilization through autophagy 
would provide the cell with new lipid quickly and without the need for the energy and time consuming processes 
of uptake and de novo synthesis.
Based on this model we hypothesized that adding LE to mice fed a high fat diet might reverse hepatic stea-
tosis through increased autophagy mediated by SREBP-2 activation. Here, we provide evidence that LE induced 
SREBP-2 activates autophagy leading to reduced lipid accumulation in the mouse liver. The results in Fig. 1 show 
that hepatic triglyceride levels are significantly reduced when HFD fed mice are supplemented with LE and this is 
accompanied by an increase in SREBP-2. Consistent with this idea, a recent report showed that LE supplementa-
tion reversed the cholesterol accumulation and liver NASH like symptoms in a mouse model fed an atherogenic 
diet27.
Our studies also show that PNPLA8, a member of the patatin family of phospholipases, is an SREBP-2 target 
gene and plays a pivotal role in LD turnover in response to LE induced SREBP-2. Furthermore, when PNPLA8 
was over-expressed in the liver of HFD fed mice, hepatic triglyceride levels were significantly lowered suggesting 
PNPLA8 was sufficient to initiate autophagic mobilization of hepatic stored triglycerides. We show that PNPLA8 
interacts directly with autophagosomes and a mutation that removed its lipase motif reduced lipid mobilization 
Figure 4. Tracking of the functional properties of Pnpla8 in vivo. Mice were sacrificed 12 days after 
transfection with control GFP (a,d) or PNPLA8-GFP expressing plasmids (b,e). Hematoxylin and eosin (H&E)-
staining (a,b) or con-focal GFP and Bodipy imaging (d,e) were performed. Triglyceride (TG) were measured 
from the tissues lysates (c). Student’s t-tests were used for the statistical analysis. *p < 0.05.
www.nature.com/scientificreports/
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but did not affect autophagosome targeting. Using time-lapsed imaging we also show evidence for a dynamic 
interaction between PNPLA8 and LC3B during autophagy induction.
Other members of the PNPLA family have been shown to contain LD targeting motifs and to be involved 
in LD mobilization28,29. PNPLA2, also called ATGL, associates with LDs and is the rate determining enzyme in 
triglyceride lipolysis30. PNPLA5 has been proposed to mobilize LD lipids for formation of the autophagosmal 
membrane13 and a PNPLA3-148M variant associates with lipid droplets and results in triglyceride accumulation 
associated with NAFLD31. However, this is the first report to demonstrate a role of PNPLA8 in LD turnover 
through activation of autophagy. PNPLA8 was first identified as a mitochondrial associated phospholipase but 
it has also been associated with the endoplasmic reticulum32 and now through our studies with the autophago-
some. The phospholipase activity of PNPLA8 produces Lysophosphatidic acid from glycerophospholipids and 
also releases a fatty acyl chain from the sn-2 position. PNPLA8 preferentially releases polyunsaturated fatty acids 
including arachidonic acid33, which can be converted into a variety of intracellular signaling lipids in addition to 
being hydrolyzed to free fatty acids for remodeling as well as oxidation. PNPLA5 has been proposed to release 
diacylglycerol from LD triglyceride that is converted into phospholipids through choline phosphotransferase 1 
to provide PL for formation of the autophagosomal membrane. This would spare organellar and plasma mem-
branes from lipid loss during autophagy. While the exact role played by PNPLA8 in lipid droplet mobilization 
through autophagy needs further investigation, it is possible that the lipid reaction products released through 
sn-2 hydrolysis generates a signaling lipid that alters mTORC1 ability to inactivate autophagy through phospho-
rylation and inactivation of the autophagy initiator kinase ULK1. Consistent with this model, we showed that 
PNPLA8 over-expression resulted in an inhibition of ULK-1 phosphorylation, which would lead to an increase 
in autophagy. This is also consistent with the recently reported increase in p-ULK1 observed in statin treated 
cardiomyocytes34. Thus, PNPLA8 may regulate autophagy initiation as well as LD turn over through inhibition of 
TORC1. It is also possible that the lysophosphatidic acid generated by PNPLA8 serves as a substrate for LPCAT 
dependent phospholipid synthesis which would augment autophagosomal membrane biogenesis. PNPLA8 is 
also subject to negative feedback regulation by long chain fatty acids33, a property that would make sense for an 
enzyme involved in activating LD turnover in response to lipid depletion.
Figure 5. PNPLA8 induces autophagy in mice fed with high-fat diet. The control GFP (a) or PNPLA8-GFP 
(b) expression vectors were injected into mice after 12 weeks of HFD fed and the MPH were prepared and 
analyzed for GFP and LC3B staining. Confocal imaging for GFP (green) and LC3B (red). (c) The number of 
LC3B puncta per cell were calculated from 10 cells, *p < 0.05. (d,e) Flow cytometric detection of acidic vacuoles 
(AVOs) of the MPH from a. (f) Immunoblots for autophagy-related proteins. Each lane is from a separate dish 
of cells from each condition analyzed separately. Data are shown as means ± standard deviations. *p < 0.05.
www.nature.com/scientificreports/
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Figure 6. PNPLA8 consumes lipid droplets and induces autophagy. (a) Deletion cartoon (upper panel) 
of serine lipase motif (Gly-x-Ser-x-Gly) from PNPLA8 amino acid sequence (lower panel). (b,c) Primary 
hepatocytes from mice fed with high-fat diet were cultured and acidic vacuoles (AVOs) from GFP vector, 
PNPLA8 + GFP (WT) or PNPLA8 Δ S493 (Mut) transfected primary hepatocytes were analyzed by FACS.  
(d) Confocal images of PNPLA8-GFP (green) and Bodipy (red) from pCMV + GFP, WT-, and Mut-transfected 
primary hepatocytes were shown, respectively. (e) Confocal images of PNPLA8-GFP (green) and LC3B (red) 
from GFP, WT-, and Mut-transfected primary hepatocytes were shown. (f) Time laps images show dynamic 
interactions between PNPLA8 and LC3 indicating an interaction between a GFP-PNPLA8-positive structure 
(green) and LC3B (red) in a lipid rich cell line. Images were acquired at the times indicated. Images are 
representative from 3 separate experiments.
www.nature.com/scientificreports/
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Taken together, our study suggests that PNPLA8 plays an active role in lipid turnover through the autophago-
some. Because PNPLA8 is activated by SREBP-2, our results also provide a mechanism for he beneficial pharma-
cologic targeting of SREBP-2 by statins in patients with NAFLD.
Materials and Methods
Animal Care. All animal experiments were performed in accordance with accepted standards of animal wel-
fare and with approval by Institutional Animal Care and Use Committee of the Ulsan National Institute of Science 
and Technology IACUC, Ulsan, Korea (protocol UNISTIACUC-14-032). C57BL/6 mice were maintained on a 
standard rodent chow diet with a 12-h light/dark cycle. Mice were separated into two groups of six animals per 
group. All mice were fed with HFD or with a normal diet (Research Diets, New Brunswick, NJ, USA). On a caloric 
basis, the HFD (product #; D12492) contained 60% fat from lard, 20% carbohydrates, and 20% proteins (total: 
23.4 kJ/g), whereas the normal diet(product #; D12450B ) contained 10% fat, 70% carbohydrate, and 20% pro-
tein (total: 12.6 kJ/g). After 12 weeks, one group of HFD mice continued on the HFD; the other two groups were 
fed either oral gavage administration with L/E [100 mg lovastatin (2.5 tablet equivalents) and 21 mg ezetimibe 
(2.1 tablet equivalents)/100 g chow, w/w]. All mice were sacrificed by CO2 asphyxiation at 8 am (at the end of 
the dark cycle). For plasmid delivery in vivo, the indicated plasmids (100 μ g with in vivo-jetPEI DNA Delivery 
Reagent (PolyPlus, New York, NY, USA) were injected into the tail veins of mice after a 12-week HFD feeding, 
according to the manufacturer’s instructions.
Figure 7. PNPLA8-mediated autophagy was regulated by mTOR inhibition. (a) 293T cells were transfected 
by the indicated plasmids. Following transfection, cells were cultured in medium with (10 μ g/ml) or without 
insulin and harvested in 30 min. The cell lysates were prepared and total and phosphorylated forms of the 
indicated proteins were analyzed by western blot. β -actin was used as a sample loading control. (b,c) The 
densitometries for pmTOR and pUlk1 blots from a were compared as β -actin blot as a control (d) Quantitative 
analysis of p-Ulk1 positive stains in HEK293 cells expressing GFP as a control, WT, or Mut. Cells were fixed and 
stained with anti-pUlk1 (S757) antibody before being analyzed by confocal microscopy. Each bar indicating the 
percent of p-Ulk1 positive stains in WT expressing cells (open bars) or in Mut expressing cells (filled bars) is 
relative to p-Ulk1 positive of GFP expressing cells. Percentage of p-Ulk1 positive cells were calculated as follow: 
(p-Ulk1 in WT cells/pUlk1 in control cells) × 100 or (p-Ulk1 in Mut cells/pUlk1 in control cells) × 100.
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Triglyceride and total cholesterol analysis. Liver tissues were homogenized in buffer containing pro-
tease inhibitors and centrifuged at 10,000 × g for 10 min at 4 °C. The supernatants were transferred to fresh tubes. 
Blood samples were allowed to clot for 30 min at 25 °C and then centrifuged at 2,000 × g for 15 min at 4 °C. The 
top yellow serum layer was removed via pipette without disturbing the white buffy layer. TG and total choles-
terol levels were measured in the soluble extracts from tissue or blood using a colorimetric assay kits (Cayman 
Chemical Company, Ann Arbor, MI, USA) according to the manufacturer’s instructions.
Hepatocyte preparation and culture. Male C57BL/6 mice fed with a 10-week HFD were used for primary 
hepatocyte isolation in all experiments. Primary mouse hepatocytes (MPH) were harvested using two-step colla-
genase perfusion35. Briefly, each animal was anesthetized with avertin (250 mg/kg) and rompun (10 mg/kg). The 
liver was perfused by sequentially injecting pre-warmed 2.5 mM EGTA (pH 7.4), a digestion buffer (0.5 mg/mL), 
collagenase type IV (Sigma, St. Louis, MO, USA), 66.7 mM NaCl, 6.7 mM KCl, 50 mM HEPES (pH 7.6), and 4.8 mM 
CaCl2 into the portal vein over a 15-min period. The digested liver was removed and shaken in 199/EBSS medium 
(Thermo Scientific, Barrington IL, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, 
USA), 1 U/mL penicillin/streptomycin (Gibco), and 10 nM dexamethasone. The resulting cell suspension was 
filtered through a 70-μ m cell strainer (BD Biosciences, San Diego, CA, USA), and the cells were pelleted and 
resuspended in 5 ml of fresh hepatocyte culture medium. The cells were overlaid on a 3% percoll solution (pH 7.4) 
and centrifuged at 700 rpm. The pelleted cells were resuspended in hepatocyte culture medium. MPH with a 
viability exceeding 95% (trypan blue exclusion analysis) were cultured further. The cells were seeded at a density 
of 4 × 105 cells/well of a 6-well plate and maintained in a humidified incubator at 37 °C with an atmosphere con-
taining 5% CO2 and treated as described in the figure legends.
RNA isolation and real-time quantitative PCR. Total RNA was isolated from mouse livers and PC-3 
cells using TRIzol (Invitrogen, Carlsbad, CA, USA) and QIAGEN RNAeasy isolation kits (QIAGEN, Valencia, 
CA, USA). Quantitative PCR reactions were performed using SYBR green fluorescent dye and a Roche 480 
(Roche, Basel, Switzerland). Relative mRNA expression levels were determined using the Δ Δ -Ct method and 
normalized to the levels of TATA-binding protein (TBP) mRNA. The sequences of all primers used in this study 
are listed in Supplementary Table S1.
Chromatin preparation for chromatin immunoprecipitation (ChIP) assays. Mouse liver chromatin 
preparations for ChIP assays were performed as previously described24,36. For gene-specific ChIP, qPCR to deter-
mine SREBP-2 binding to specific gene promoters was analyzed in triplicate using a standard dilution curve of the 
input DNA performed in parallel, and enrichment was measured by SYBR green incorporation on a Roche 480. 
Analysis was performed using the standard curve method, and values were normalized to a non-target control 
region from the ribosomal Rplpo gene.
Cell culture and RNA interference. MPH were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% heat-inactivated fetal calf serum and antibiotics at 37 °C in an atmosphere with 
5% CO2. PNPLA8 specific- siRNA (SR309408; Origene, USA) and control siRNAs (sc-37007) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were transfected for 24 h with 10 nM of each siRNA 
and Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer’s instructions; subsequently, 
plates and chamber slides were washed and refilled with fresh media with or without serum for 24 h followed by 
analysis.
Immunoblotting. A polyclonal rabbit antibodies were carefully evaluated their selectivity and specificity for 
SREBP-2 or SREBP-1 in our previous papers12,24,36. Hepatic nuclear protein and whole-cell lysates were subjected 
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (7%, 10%, or 12%), followed by transfer to nitro-
cellulose membranes and blocked with Tris-buffered saline with 0.02% Tween (TBST) containing 5% milk for 2 h. 
Membranes were incubated overnight with primary antibodies against AKT (Cell Signaling, 9272), phospho-AKT 
(S473; Cell Signaling, #9271), Ulk1(Cell signaling, #8054S), phospho-Ulk1 (Ser757; Cell Signaling, #6888S), and 
mTOR (Santa Cruz Biotechnology, sc-8319), phospho-mTOR (S2448; Santa Cruz Biotechnology, sc-101738). 
Membranes were washed in TBST and incubated with appropriate secondary horseradish peroxidase-conjugated 
antibodies (Bio-Rad, Richmond, CA). All images were acquired from Image Lab (Ver. 4.1) of ChemiDoc Imaging 
System (BIO-RAD, USA) and transformed in AutoScale where Gamma ray was 1.0. Each WB image as shown as 
representative figure was actually cropped and displayed in the main figures.
PNPLA8-GFP and mutant-GFP plasmid constructs for detecting Ulk1 activity. cDNAs encod-
ing PNPLA8 or GXSXG-deleted PNPLA8 were cloned into pCMV-GFP vector according to the manufacturer’s 
instruction. HEK-293 cells were transfected with the DNA constructs (control pCMV-GFP, pCMV-WT-GFP, 
and pCMV-Mut-GFP) after seeding in 6-well plates following the manufacturer’s protocol. After 24 hr 
post-transfection, the cells were treated with insulin for 30 min to final concentration of 5 ug/ml. For detection 
of Ulk phosphorylation, cells were and washed twice with ice-cold PBS. Subsequently, cells were lysed in buffer 
consisting of 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40 
(Sigma-Aldrich, 74385), 0.1% sodium dodecyl sulfate, 1 mM PMSF, 1 mM sodium fluoride, 1 mM sodium ortho-
vanadate, and protease inhibitor cocktail. For ULK1 localization, HEK293 cells harboring the plasmid constructs 
were fixed and imaged for GFP fluorescence as followed.
Immunofluorescence and immunohistochemistry. Sections of paraffin-embedded livers were 
dewaxed in xylene, rehydrated, and subjected to antigen retrieval in 10 mM citrate buffer. Sections were blocked 
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for 30 min in 1% bovine serum albumin, 0.02% Triton X-100, and 10% normal goat serum (NGS). Serial sec-
tions were incubated with rabbit polyclonal SREBP-2 antibody (1:500 dilution), followed by Cy5-conjugated goat 
anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). The sec-
tions were mounted using Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA). Images from 
serial sections were acquired using an Axioskop inverted microscope with an AxioVision camera and software 
(Zeiss, Thornwood, NY, USA). For immunocytochemistry, PC-3 cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.25% Triton X-100, blocked with 10% NGS, and incubated with anti-LC3B primary anti-
body, followed by Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody before mounting. Lipid drop-
lets were stained by incubating cells with BODIPY 493/503 (Invitrogen) for 30 min, followed by fixation and 
immunofluorescence processing as described above. Images of cells were acquired with a laser scanning confocal 
microscope (A1R VAAS with a 3 60/numerical aperture 1.49 oil-immersion lens; Nikon, Melville, NY, USA) and 
NIS-Elements AR software (Nikon). For all experiments, approximately 30 cells per sample were counted, and 
triplicate samples were counted for each experimental condition. Autophagy quantification was performed with 
the “Analyze Particle” function of ImageJ software (National Institutes of Health, Bethesda, MD, USA). To quan-
tify co-localization, the ImageJ JACoP plug-in ref. 37 was used to calculate the percentage of co-localization from 
Manders’s overlapping coefficients (i.e., the fraction of red that overlaps green)38.
Detection of acidic vesicular organelles: AVOs. To detect AVOs, MPH cells were cultured in a 
glass-bottomed dish in DMEM with 10% FBS and antibiotics. After treatment with lovastatin for 24 h, the cells 
were stained with 1 μ M AO at 37 °C in the dark for 20 min. Next, the cells were washed with PBS and visualized 
using a laser-scanning confocal microscope (Fluoview FV1000; Olympus, Tokyo, Japan). Acridine orange stains 
DNA green in healthy cells and turns orange when it is sequestered into lysosomes and becomes protonated. To 
quantify the number of AVOs, the cells were harvested with trypsin treatment and washed with PBS. Next, the 
cells were analyzed by flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, USA), and the pop-
ulation frequencies were calculated using Cell Quest Pro software (Becton Dickinson) for Mac® OS 9.
Live Cell Imaging. PC-3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) and sup-
plemented with 10% (v/v) fetal bovine serum (FBS) (GIBCO) and 1/100 (v/v) Pen/Strep (GIBCO). Cells were 
maintained at 37 °C with 5% CO2 for the duration of the experiment. For transfections, cells were grown to 
80% confluency in four chambered cover-glass system (Lab-TekII, NUNC, USA) and co-transfected with 4 μ g 
of LC3B-RFP plus pCMV- GFP and LC3B-RFP plus PNPLA8-GFP plasmid DNAs, respectively per chamber 
using lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s instructions. After 24 h of transfec-
tion, cells were washed with a fresh complete DMEM. Cells were examined in an inverted microscope. Confocal 
images were obtained with a Zeiss LSM 780 laser confocal microscope (Carl Zeiss MicroImaging, Inc.) using a 
63_oil-immersion objective equipped with an objective heater.
Statistical analysis. Experiments were repeated at least three times with consistent results. Unless other-
wise stated, data are expressed as the means ± standard deviations. An analysis of variance was used to compare 
experimental and control values. Comparisons between multiple groups were performed using Tukey’s multiple 
comparison test. Results were considered statistically significant at a p value of < 0.05.
References
1. Ogden, C. L. et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295, 1549–1555 (2006).
2. Flegal, K. M., Ogden, C. L. & Carroll, M. D. Prevalence and trends in overweight in Mexican-american adults and children. Nutr Rev 
62, S144–S148 (2004).
3. Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J 
Hepatol 59, 550–556 (2013).
4. Poirier, P. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 
American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on 
Nutrition, Physical Activity, and Metabolism. Circulation 113, 898–918 (2006).
5. Unger, R. H. Lipotoxic diseases. Annu Rev Med 53, 319–336 (2002).
6. Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver 
disease. J Clin Invest 115, 1343–1351 (2005).
7. Choi, S. S. & Diehl, A. M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19, 295–300 (2008).
8. Shimomura, I., Shimano, H., Horton, J. D., Goldstein, J. L. & Brown, M. S. Differential expression of exons 1a and 1c in mRNAs for 
sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99, 838–845 (1997).
9. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in 
the liver. J Clin Invest 109, 1125–1131 (2002).
10. Yokoyama, C. et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density 
lipoprotein receptor gene. Cell 75, 187–197 (1993).
11. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound 
transcription factor. Cell 89, 331–340 (1997).
12. Seo, Y. K. et al. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab 13, 367–375 
(2011).
13. Dupont, N. et al. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. Curr Biol 24, 609–620 (2014).
14. Lake, A. C. et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res 46, 
2477–2487 (2005).
15. Murakami, M. et al. Group VIB Ca2 + -independent phospholipase A2gamma promotes cellular membrane hydrolysis and 
prostaglandin production in a manner distinct from other intracellular phospholipases A2. J Biol Chem 280, 14028–14041 (2005).
16. Ramanadham, S. et al. Calcium-independent phospholipases A2 and their roles in biological processes and diseases. J Lipid Res 56, 
1643–1668 (2015).
17. Jenkins, C. M. et al. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase 
A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 279, 48968–48975 (2004).
www.nature.com/scientificreports/
13Scientific RepoRts | 6:35732 | DOI: 10.1038/srep35732
18. Kienesberger, P. C., Oberer, M., Lass, A. & Zechner, R. Mammalian patatin domain containing proteins: a family with diverse 
lipolytic activities involved in multiple biological functions. J Lipid Res 50 Suppl, S63–S68 (2009).
19. Huang, Y. et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA 107, 7892–7897 (2010).
20. Mancuso, D. J., Jenkins, C. M. & Gross, R. W. The genomic organization, complete mRNA sequence, cloning, and expression of a 
novel human intracellular membrane-associated calcium-independent phospholipase A(2). J Biol Chem 275, 9937–9945 (2000).
21. Mancuso, D. J. et al. Genetic ablation of calcium-independent phospholipase A2{gamma} leads to alterations in hippocampal 
cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. J Biol 
Chem 284, 35632–35644 (2009).
22. Mancuso, D. J. et al. Genetic ablation of calcium-independent phospholipase A2gamma leads to alterations in mitochondrial lipid 
metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J Biol Chem 282, 34611–34622 (2007).
23. Nseir, W. & Mahamid, M. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. Curr Atheroscler Rep 15, 305 
(2013).
24. Seo, Y. K. et al. Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal 
binding to a new motif. Proc Natl Acad Sci USA 106, 13765–13769 (2009).
25. Parihar, S. P. et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing 
autophagy and phagosome maturation. J Infect Dis 209, 754–763 (2014).
26. Ou, J. et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by 
antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 98, 6027–6032 (2001).
27. Ioannou, G. N. et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like 
structures during resolution of NASH. J Lipid Res 56, 277–285 (2015).
28. Murugesan, S., Goldberg, E. B., Dou, E. & Brown, W. J. Identification of diverse lipid droplet targeting motifs in the PNPLA family 
of triglyceride lipases. PLoS One 8, e64950 (2013).
29. Rabinowitz, J. D. & White, E. Autophagy and metabolism. Science 330, 1344–1348 (2010).
30. Zechner, R., Kienesberger, P. C., Haemmerle, G., Zimmermann, R. & Lass, A. Adipose triglyceride lipase and the lipolytic catabolism 
of cellular fat stores. J Lipid Res 50, 3–21 (2009).
31. Smagris, E. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61, 
108–118 (2015).
32. Kinsey, G. R. et al. Identification and distribution of endoplasmic reticulum iPLA2. Biochem Biophys Res Commun 327, 287–293 
(2005).
33. Moon, S. H. et al. Activation of mitochondrial calcium-independent phospholipase A2gamma (iPLA2gamma) by divalent cations 
mediating arachidonate release and production of downstream eicosanoids. J Biol Chem 287, 14880–14895 (2012).
34. Andres, A. M. et al. Mitophagy is required for acute cardioprotection by simvastatin. Antioxid Redox Signal 21, 1960–1973 (2014).
35. Gandin, V. et al. Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature 455, 684–688 
(2008).
36. Bennett, M. K., Seo, Y. K., Datta, S., Shin, D. J. & Osborne, T. F. Selective binding of sterol regulatory element-binding protein 
isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver. J Biol Chem 283, 15628–15637 (2008).
37. Bolte, S. & Cordelieres, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224, 213–232 
(2006).
38. Manders, E. M., Stap, J., Brakenhoff, G. J., van Driel, R. & Aten, J. A. Dynamics of three-dimensional replication patterns during the 
S-phase, analysed by double labelling of DNA and confocal microscopy. J Cell Sci 103 (Pt 3), 857–862 (1992).
Acknowledgements
We thank Jinhoe Hur from the UNIST Olympus-Biomed imaging Center (UOBC) at UNIST for excellent 
technical assistance with the confocal and super resolution imaging analysis. We also thank Dr. Richard Gross for 
thoughtful discussion. We thank Christine Lauretano from Sanford Burnham Prebys Medical Discovery Institute 
for help with preparation and submission of the manuscript. This work was supported by the Basic Science 
Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of 
Education, Science, and Technology grants 2014M3A9D8034459 and 2016R1D1A1B01009681 and NHLBI 
(HL48044).
Author Contributions
Y.-K.S. planned the experiment and analyzed the data. K.-Y.K., K.-I.P., H.-J.J., Y.-R.Y., J.K.S., I.-W.S. and S.-c.A. 
performed the material experiments. Y.-K.S., T.-I.J., P.-G.S. and T.F.O. analyzed data and wrote the manuscript. 
Y.-K.S. supervised the project.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Kim, K.-Y. et al. SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease 
through activation of autophagy. Sci. Rep. 6, 35732; doi: 10.1038/srep35732 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
